The cancer genome has
more to reveal.
Arima Genomics is building DNA-based cancer diagnostics that bring sequence and structure together to find more of what drives disease — creating new opportunities to guide therapy and bring more patients closer to the right treatment.
More of the genome.
More of what matters.
Cancer is driven by changes across DNA, from sequence alterations to structural events that reshape how genes function. Arima pairs genomic sequence with structural information to capture DNA-level changes conventional approaches were not built to see.
That foundation powers Aventa clinical testing and guides Arima’s work across translational science, biopharma partnerships, and platform innovation — moving cancer diagnostics toward a future where more genomic answers can come from one tissue-efficient assay.
Arima’s pioneering work in 3D genome science enables detection of structural events that change how cancer genes function — from fusions and rearrangements to enhancer hijacking, ecDNA, and other mechanisms that can affect therapy selection.
By connecting genome structure with DNA sequence, Arima can expose hidden drivers, uncover new biomarker opportunities, and create new paths for clinical and therapeutic development.
Structure adds the missing dimension.
Clinical testing built on structural insight.
Aventa is the clinical testing brand from Arima Genomics, bringing the company’s Hi-C sequencing technology into cancer care through tests designed for routine FFPE samples. Aventa tests include Aventa FusionPlus for solid tumors and Aventa Lymphoma.
Built on Arima’s structural readout of the cancer genome, Aventa helps clinicians find fusions and rearrangements that conventional workflows may miss or incompletely characterize — supporting more complete diagnosis, prognosis, and therapy selection.
Aventa FusionPlus
Find what conventional testing can miss.
Detect clinically relevant fusions and rearrangements that can guide therapy selection or support diagnosis in solid tumors.
Aventa Lymphoma
Go beyond targeted testing.
Identify clinically relevant rearrangements that can inform diagnosis, classification, prognosis, and treatment planning.
Expanding structural insight across oncology.
-
Biopharma partnerships
Arima partners with biopharma teams to connect structural cancer drivers to therapeutic opportunity — identifying biomarker-defined patient populations, informing development strategy, and expanding the reach of targeted therapies.
-
Translational science
Arima collaborates with leading scientists around the world to study cancer-driving structural mechanisms made visible by Hi-C sequencing, including enhancer hijacking, ecDNA, and other emerging classes of genomic alteration.
From 3D genome discovery to clinical impact
Arima Genomics was founded by leaders in 3D genome science and built on the belief that genome structure holds critical information about disease. Today, Arima applies that expertise through Aventa clinical tests, biopharma partnerships, and platform innovation — redefining cancer diagnostics by revealing more of what drives disease and advancing a more complete DNA-based view of cancer.